BioXcel Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference
BioXcel Therapeutics (Nasdaq: BTAI), a biopharmaceutical company focusing on AI-driven neuroscience and immuno-oncology medicines, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference. The event will take place in Boston on August 13, 2024.
CEO Vimal Mehta, Ph.D., will engage in a fireside chat at 1 p.m. ET, accompanied by Vincent J. O'Neill, M.D., Executive VP and Chief of Product Development and Medical Officer. Interested parties can access a live webcast of the discussion through the company's website. The replay will be available for 90 days post-event.
BioXcel Therapeutics (Nasdaq: BTAI), un'azienda biofarmaceutica che si concentra su medicine neuroscientifiche e immuno-oncologiche guidate dall'IA, ha annunciato la sua partecipazione alla 44ª Conferenza Annuale sulla Crescita di Canaccord Genuity. L'evento si terrà a Boston il 13 agosto 2024.
Il CEO Vimal Mehta, Ph.D., parteciperà a una conversazione informale alle 13:00 ET, insieme a Vincent J. O'Neill, M.D., VP Esecutivo e Direttore dello Sviluppo Prodotti e Direttore Medico. Le parti interessate possono accedere a una diretta streaming della discussione attraverso il sito web dell'azienda. La registrazione sarà disponibile per 90 giorni dopo l'evento.
BioXcel Therapeutics (Nasdaq: BTAI), una empresa biofarmacéutica que se centra en medicamentos de neurociencia e inmuno-oncología impulsados por IA, ha anunciado su participación en la 44ª Conferencia Anual de Crecimiento de Canaccord Genuity. El evento se llevará a cabo en Boston el 13 de agosto de 2024.
El CEO Vimal Mehta, Ph.D., participará en una charla al calor del fuego a la 1 p.m. ET, acompañado por Vincent J. O'Neill, M.D., VP Ejecutivo y Jefe de Desarrollo de Productos y Director Médico. Las partes interesadas pueden acceder a una transmisión en vivo de la discusión a través del sitio web de la empresa. La grabación estará disponible durante 90 días después del evento.
BioXcel Therapeutics (Nasdaq: BTAI)는 AI 기반 신경과학 및 면역 종양학 약물에 중점을 둔 생명공학 회사로, Canaccord Genuity 제44회 연례 성장 컨퍼런스에 참여한다고 발표했습니다. 이 행사는 2024년 8월 13일 보스턴에서 열릴 예정입니다.
CEO Vimal Mehta, Ph.D.는 오후 1시 ET에 Vincent J. O'Neill, M.D., 임상 개발 및 의료 책임자와 함께 대화에 참여합니다. 관심 있는 분들은 회사 웹사이트를 통해 토론의 생중계를 이용할 수 있습니다. 이벤트 후 90일 동안 다시 볼 수 있습니다.
BioXcel Therapeutics (Nasdaq: BTAI), une entreprise biopharmaceutique axée sur les médicaments de neurosciences et d'immuno-oncologie pilotés par l'IA, a annoncé sa participation à la 44e Conférence Annuelle de Croissance de Canaccord Genuity. L'événement aura lieu à Boston le 13 août 2024.
Le PDG Vimal Mehta, Ph.D. participera à une conversation informelle à 13h ET, en compagnie de Vincent J. O'Neill, M.D., VP Exécutif et Directeur du développement des produits et Médecin en Chef. Les parties intéressées peuvent accéder à un webinaire en direct de la discussion via le site Web de l'entreprise. La rediffusion sera disponible pendant 90 jours après l'événement.
BioXcel Therapeutics (Nasdaq: BTAI), ein biopharmazeutisches Unternehmen, das sich auf KI-gesteuerte Neurowissenschaften und immunonkologische Medikamente konzentriert, hat seine Teilnahme an der 44. jährlichen Wachstums-Konferenz von Canaccord Genuity bekannt gegeben. Die Veranstaltung findet am 13. August 2024 in Boston statt.
CEO Vimal Mehta, Ph.D. wird ab 13:00 Uhr ET an einem informellen Gespräch teilnehmen, begleitet von Vincent J. O'Neill, M.D., Executive VP und Leiter der Produktentwicklung sowie Chief Medical Officer. Interessierte können über die Website des Unternehmens auf einen Live-Stream der Diskussion zugreifen. Die Wiederholung wird 90 Tage nach der Veranstaltung verfügbar sein.
- None.
- None.
NEW HAVEN, Conn., Aug. 07, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics, will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference in Boston on Tuesday, August 13, 2024 at 1 p.m. ET. Dr. Mehta will be joined by Vincent J. O’Neill, M.D., Executive Vice President, Chief of Product Development and Medical Officer.
To access a live webcast of the fireside chat, please visit the Events & Presentations page under the “News/Events” tab in the Investors & Media section of the Company’s website at bioxceltherapeutics.com. A webcast replay will be available for 90 days.
About BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. Its wholly owned subsidiary, OnkosXcel Therapeutics, is focused on the development of medicines in immuno-oncology. The Company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications. For more information, please visit bioxceltherapeutics.com.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release other than statements of historical fact should be considered forward-looking statements, including, without limitation, statements related to the Company’s planned participation in and content of the Company’s fireside chat at the Canaccord Genuity 44th Annual Growth Conference, including the date and time of such event. When used herein, words including “anticipate,” “believe,” “can,” “continue,” “could,” “designed,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon the Company’s current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation: its limited operating history; its incurrence of significant losses; its need for substantial additional funding and ability to raise capital when needed; the impact of the reprioritization; its significant indebtedness, ability to comply with covenant obligations and potential payment obligations related to such indebtedness and other contractual obligations; the Company has identified conditions and events that raise substantial doubt about its ability to continue as a going concern; its limited experience in drug discovery and drug development; risks related to the TRANQUILITY program; its dependence on the success and commercialization of IGALMI™, BXCL501, BXCL502, BXCL701 and BXCL702 and other product candidates; its lack of experience in marketing and selling drug products; the risk that IGALMI or the Company’s product candidates may not be accepted by physicians or the medical community in general; the Company still faces extensive and ongoing regulatory requirements and obligations for IGALMI; the failure of preliminary data from its clinical studies to predict final study results; failure of its early clinical studies or preclinical studies to predict future clinical studies; its ability to receive regulatory approval for its product candidates; its ability to enroll patients in its clinical trials; undesirable side effects caused by the Company’s product candidates; its novel approach to the discovery and development of product candidates based on EvolverAI; the significant influence of and dependence on BioXcel LLC; its exposure to patent infringement lawsuits; its reliance on third parties; its ability to comply with the extensive regulations applicable to it; impacts from data breaches or cyber-attacks, if any; risks associated with the increased scrutiny relating to environmental, social and governance (ESG) matters; risks associated with federal, state or foreign health care “fraud and abuse” laws; and its ability to commercialize its product candidates, as well as the important factors discussed under the caption “Risk Factors” in its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024, as such factors may be updated from time to time in its other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov and the Investors section of the Company’s website at www.bioxceltherapeutics.com. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.
Contact Information
Corporate
BioXcel Therapeutics
Erik Kopp
1.203.494.7062
ekopp@bioxceltherapeutics.com
Investors
Russo Partners
Nic Johnson
1.303.482.6405
Nic.Johnson@russopartnersllc.com
Media
Russo Partners
David Schull
1.858.717.2310
David.schull@russopartnersllc.com
Source: BioXcel Therapeutics, Inc.
FAQ
When is BioXcel Therapeutics (BTAI) participating in the Canaccord Genuity Growth Conference?
Who will represent BioXcel Therapeutics (BTAI) at the Canaccord Genuity conference?
What time is BioXcel Therapeutics' (BTAI) fireside chat at the Canaccord Genuity conference?
How can investors access BioXcel Therapeutics' (BTAI) presentation at the Canaccord Genuity conference?
How long will the webcast replay of BioXcel Therapeutics' (BTAI) presentation be available?
